Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the ten research firms that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $56.00.
A number of brokerages have recently commented on COAG. Weiss Ratings lowered shares of Hemab Therapeutics from a "sell (d+)" rating to a "sell (d)" rating in a research report on Friday, September 25th. HC Wainwright increased their price target on Hemab Therapeutics from $52.00 to $60.00 and gave the stock a "buy" rating in a research report on Tuesday, August 11th. JPMorgan Chase & Co. initiated coverage on Hemab Therapeutics in a research note on Thursday, October 15th. They set an "overweight" rating and a $70.00 price target on the stock. Lifesci Capital initiated coverage on Hemab Therapeutics in a report on Monday, November 9th. They issued an "outperform" rating and a $65.00 price objective for the company. Finally, Wedbush boosted their price target on shares of Hemab Therapeutics from $55.00 to $64.00 and gave the company an "outperform" rating in a report on Wednesday, August 12th.
View Our Latest Stock Report on Hemab Therapeutics
Hemab Therapeutics Stock Performance
Shares of NASDAQ COAG opened at $39.86 on Friday. The company's 50-day moving average is $36.72. Hemab Therapeutics has a 52-week low of $23.00 and a 52-week high of $55.42. The stock has a market cap of $1.86 billion and a P/E ratio of -1.57.
Hemab Therapeutics (NASDAQ:COAG - Get Free Report) last announced its earnings results on Tuesday, November 10th. The company reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.07). As a group, equities research analysts forecast that Hemab Therapeutics will post -3.23 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in COAG. State Street Corp boosted its stake in shares of Hemab Therapeutics by 1,105.8% during the third quarter. State Street Corp now owns 927,245 shares of the company's stock valued at $28,596,000 after acquiring an additional 850,345 shares during the last quarter. Citadel Advisors LLC acquired a new position in shares of Hemab Therapeutics in the 2nd quarter valued at about $19,226,000. Braidwell LP acquired a new position in shares of Hemab Therapeutics in the 2nd quarter valued at about $5,877,000. Opaleye Management Inc. purchased a new stake in shares of Hemab Therapeutics in the second quarter worth approximately $1,750,000. Finally, Goldman Sachs Group Inc. purchased a new stake in shares of Hemab Therapeutics in the third quarter worth approximately $1,684,000.
About Hemab Therapeutics
(
Get Free Report)
Hemab Therapeutics is a clinical-stage biotechnology company developing treatments for serious bleeding and thrombotic disorders, with a focus on conditions that have limited treatment options. Its research centers on therapies intended to help restore or regulate blood clotting. The company's lead candidate, HMB-001, is an investigational bispecific antibody being developed for Glanzmann thrombasthenia, a rare inherited bleeding disorder. Hemab is also advancing research into additional disorders affecting hemostasis, the process that helps the body control bleeding.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Hemab Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hemab Therapeutics wasn't on the list.
While Hemab Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.